Haemonetics (HAE) Misses Q4 EPS by 21c, Revenues Beat; Offers FY22 EPS Guidance Above Consensus

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/4/2026

1. AAPL
2. AMD
3. PLTR
4. CRWD
5. DOX
6. VRTX
7. CHKP
8. ON
9. INSP
10. CVI

Go back to Haemonetics (HAE) Misses Q4 EPS by 21c, Revenues Beat; Offers FY22 EPS Guidance Above Consensus

Haemonetics (HAE) PT Lowered to $86 at Needham & Company

May 13, 2021 1:03 PM EDT

Needham & Company analyst Mike Matson lowered the price target on Haemonetics (NYSE: HAE) to $86.00 (from $108.00) while maintaining a Buy rating.

The analyst commented, "HAE's F4Q21 revenue beat and EPS missed consensus. HAE's organic growth slowed to (13.7%) in F4Q21 vs. (5.7%)... More

Jefferies Sees Haemonetics (HAE) as Oversold Ahead of Earnings, PT Lowered $105

May 12, 2021 8:10 AM EDT

Jefferies analyst Anthony Petrone lowered the price target on Haemonetics (NYSE: HAE) to $105.00 (from $185.00) ahead of the F4Q earnings call scheduled for 5/13 BMO. Focus points for the call are expected to include: 1) detail/commentary on CSL's plasma supply chain shift toward Terumo; 2) future contracting implications, 3)... More